A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Herceptin|DRUG: Docetaxel|DRUG: Pertuzumab
Sponsor: Hoffmann-La Roche